PHILADELPHIA, Nov. 1, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it will release third quarter 2013 financial results on Thursday, November 7, 2013. Management will hold a conference call to review the company's third quarter 2013 performance starting at 9:00 a.m. ET on the same day.
The dial-in number is (877) 300-8521 and reference Echo Therapeutics 3rd Quarter 2013 Earnings Call. The archived audiocast will be available for fourteen days following the call by visiting the Events section of Echo's website at www.echotx.com.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.
For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
|SOURCE Echo Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved